BioPharmSignal logoBioPharmSignal

Biotech News

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine (PRME)Prime MedicineEarnings

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in

Open original release

Related news

PRMEPrime Medicine2026-05-07 12:00 EST

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-03-03 13:00 EST

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

View all latest news

Prime Medicine

Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases. The platform aims to expand the precision and flexibility of genome editing.

Recent company news

PRMEPrime Medicine2026-06-03 12:00 EST

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

PRMEPrime Medicine2026-05-07 12:00 EST

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-04-16 12:00 EST

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

PRMEPrime Medicine2026-03-03 13:00 EST

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-02-25 13:00 EST

Prime Medicine to Participate in Upcoming Investor Conferences

Stock data

Close
3.01 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States